CEO · Founder, CERTA TherapeuticsTreatment of fibrotic diseases
| Role | Organisation | Sources |
|---|---|---|
| CEO (former) | CERTA Therapeutics | Brandon BioCatalyst |
| CEO · Founder | CERTA TherapeuticsTreatment of fibrotic diseases | Brandon BioCatalyst, Brandon Capital (Thu 19 Dec 2024), Brandon Capital (Thu 16 Nov 2023) |
| Executive Chair | OccuRx | Startup Daily, Brandon BioCatalyst portfolio, Brandon Capital portfolio |
Stories naming Professor Darren Kelly. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech Certa Therapeutics has acquired OccuRx, combining two GPR68 fibrosis pipelines founded by Professor Darren Kelly, and says it will seek Series B funding to advance clinical development.
Melbourne biotech Certa Therapeutics reported encouraging Phase 2 results for its scleroderma drug FT011 at a US rheumatology meeting, with safety confirmed and a pivotal trial planned.
Australian biotech Certa Therapeutics reports Phase 2 scleroderma trial results for FT011 at a US rheumatology meeting, showing efficacy and safety, with a pivotal study planned.
Australian biotech OccuRx secured $16 million co-led by Brandon BioCatalyst and Uniseed, including a CUREator grant, to advance its oral anti-fibrosis therapy into kidney disease trials; two executives also joined.